Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 14 October 2020, 12:00 HKT/SGT
Share:
Broncus Closes Series C Financing
Funds Will Support Further Development of Interventional Technologies for Navigation and Treatment of Diseases Across the Lung

HONG KONG, Oct 14, 2020 - (ACN Newswire) - Broncus Holding Company ("Broncus"), a global leader in diagnostic and therapeutic technology for lung diseases, today announced the closing of a Series C round of funding led by Lake Bleu Capital, and including Baidu Capital, the venture arm of one of the world's largest Internet and data science companies, Ascendum Capital, CNCB Capital and DCP Capital, along with previous investor Qiming Venture Capital.




The funds will be used to further develop markets and technology across lung cancer, emphysema and other important lung diseases. Efforts will include expanding global market adoption of the Archimedes Virtual Bronchoscopic Navigation System combining Fused Fluoroscopy, real-time bronchoscopy and virtual bronchoscopic navigation for 3D views and access to nodules anywhere in the lungs; expanded commercial adoption and global clinical studies of the InterVapor System for Bronchoscopic Thermal Vapor Ablation (BTVA) used in emphysema; U.S. and European studies of the EMPOWER RF Catheter used in Bronchoscopic Radiofrequency Ablation (BRFA); and further development of next-generation RF technology to precisely treat lung nodules.

Zhan Guowei, CEO of Broncus, said, "In recent years, medical device leaders such as Medtronic and Johnson & Johnson have invested in the market development of technologies for lung disease, which validates our forward-looking vision to focus exclusively on the diagnosis and treatment of diseases in the lung. Securing investors such as Lake Bleu Capital, Baidu Capital and Intuitive Surgical further supports our strategy to 'own' the lung when it comes to diagnosis and treatment. Our breakthrough navigation technology is enabling us to accelerate the development and commercialization of precise interventional technologies for diagnosis and treatment in order to improve options for patients with lung diseases and the physicians that care for them."

Dr. Li Bin, founder of Lake Bleu Capital, said: "Broncus is Lake Bleu's major investment in the medical device sector this year because they are addressing a large and unmet need globally in the diagnosis and treatment of lung diseases. Their world-leading Archimedes lung navigation technology is supported with robust data and uniquely helps physicians accurately locate and reach targeted lesions, which will open the door to new and exciting interventional lung therapies. We believe that Broncus is well positioned to lead the world in providing less invasive methods to diagnose and treat lung disease broadly."

Broncus recently announced a new strategic partnership with Olympus Europa to exclusively distribute Broncus Medical's Archimedes Planner and Archimedes Lite Virtual Bronchoscopic Navigation (VBN) system in several European countries.

Early investors in the company include Intuitive Surgical, an early pioneer and global technology leader in minimally invasive, robotic-assisted surgery.

About Broncus Holding Company
Broncus is dedicated to the development of diagnostic and therapeutic technology for lung disease. Founded in 2012, the company's primary technology platforms focus on the diagnosis of lung cancer and the treatment of emphysema. Its lung cancer portfolio includes the Archimedes System, Archimedes Planner, LungPoint Virtual Bronchoscopic Navigation (VBN) System, LungPoint Planner and FleXNeedle.

The Archimedes System has been cleared by the FDA (U.S.), CE (Europe) and NMPA (China) and had broad patent protection globally. The InterVapor System has received the CE Mark.

About Lake Bleu Capital
Lake Bleu Capital is an investment platform that specializes in healthcare in Asia/Greater China. As one of the largest healthcare public equity funds in Asia, the USD public equity fund under Lake Bleu Capital has won multiple industry-leading performance awards for the region of Asia ex-Japan. Meanwhile, Lake Bleu Capital has also focused on private equity investments in the Chinese healthcare industry, successfully completing multiple investments in flagship innovative companies across different healthcare subsectors.

Media Contact:
Broncus
Shirley Deng Email: [email protected]



Oct 14, 2020 12:00 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, BioTech, Healthcare & Pharm, Venture Capital
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Epazz DeskFlex Room Booking System Sees Demand Coming From Asia Pacific Region; Advances COVID-Compliant Software Suite For Specific Functionality  
Oct 22, 2020 01:00 HKT/SGT
US Tests Confirm Path-Away(R) Organically Kills SARS-CoV-2 Virus  
Oct 21, 2020 21:00 HKT/SGT
Building Environmental Awareness through Religious Leaders Training on Peatland and Conservation  
Oct 21, 2020 19:00 HKT/SGT
TEC presents Welcome Back To The Office! Good to leave, even better to.. come back?  
Oct 21, 2020 11:11 HKT/SGT
Buick Electra Electric Crossover Concept Glides at Global Premiere  
Oct 21, 2020 09:00 HKT/SGT
Pacific Green Acquires Battery Energy Storage System Design Company Innoergy Limited  
Oct 20, 2020 21:00 HKT/SGT
Tak Lee Machinery Announces 2019/2020 Annual Results  
Oct 20, 2020 19:47 HKT/SGT
Lvji Technology Listed in Forbes Asia's Best Under A Billion 2020  
Oct 20, 2020 18:00 HKT/SGT
The Babylon Project concludes with developers from 65 Countries  
Oct 20, 2020 18:00 HKT/SGT
MHI Again Receives EcoVadis Silver Rating for Overall Sustainability  
Oct 20, 2020 14:54 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: